| HOME >> BIOLOGY >> TECHNOLOGY |
Notes to Editors
About Prostate Cancer
Prostate cancer primarily affects men over the age of 50.(3) It is the most commonly diagnosed male cancer in many western countries and its incidence is increasing. Worldwide, more than 670,000 men are diagnosed with prostate cancer every year, accounting for one in nine of all new cancers in men. Prostate cancer is the second most common cancer in men after lung cancer.(4) HRPC affects approximately 60,000 new patients in the US alone each year.(5)
About AstraZeneca
AstraZeneca is a major international health care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of health care services. It is one of the world's leading pharmaceutical companies with health care sales of $26.475 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology, and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.
For more information visit:
References:
(1) James, M.D. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases.
(2) Morris, C.D. et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. British Journal of Cancer. 2005: 92
(3) Kirby RS et al. Prostate cancer and sexual function. Prostate
Cancer and Prosta
'/>"/>
| SOURCE AstraZeneca Copyright©2007 PR Newswire. All rights reserved |